Literature DB >> 18676751

T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival.

Stephen A Boorjian1, Yuri Sheinin, Paul L Crispen, Sara A Farmer, Christine M Lohse, Susan M Kuntz, Bradley C Leibovich, Eugene D Kwon, Igor Frank.   

Abstract

PURPOSE: Aberrant expression of T-cell coregulatory molecules has been investigated as a mechanism by which certain cancers may evade host immune surveillance. We evaluated expression of the T-cell coregulators B7-H1, B7-H3, and PD-1 in urothelial cell carcinoma (UCC) of the bladder. EXPERIMENTAL
DESIGN: Immunohistochemistry for B7-H1, B7-H3, and PD-1 was done on paraffin-embedded sections from 318 consecutive patients with UCC who underwent radical cystectomy. Expression was correlated with clinicopathologic outcomes and postoperative survival.
RESULTS: B7-H3 was widely expressed in UCC, as 222 of 314 (70.7%) tumors showed positive staining. Expression of B7-H3 in UCC was significantly increased compared with adjacent, nontumor urothelium, as a median of 70% of tumor cells expressed B7-H3, compared with 20% of cells in nontumor specimens (P < 0.001). The increase in B7-H3 expression was independent of tumor stage (P = 0.13). Expression of B7-H1 by UCC tumors (P < 0.001) and PD-1 by tumor-infiltrating lymphocytes (P = 0.012) were significantly associated with increased pathologic stage. Patients who had received intravesical bacillus Calmette-Guerin before cystectomy tended to show increased expression of B7-H3 (P = 0.023) and PD-1 (P = 0.071) but were less likely to express B7-H1 (P = 0.027). Moreover, for the subset of patients with organ-confined disease (n = 167), B7-H1 expression independently predicted all-cause mortality after cystectomy (hazard ratio, 3.18; 95% confidence interval, 1.74-5.79; P < 0.001).
CONCLUSIONS: B7-H3 is highly expressed in UCC across tumor stages, whereas B7-H1 and PD-1 expression are associated with advanced disease. B7-H1 expression predicts mortality after cystectomy for patients with organ-confined tumors. These molecules may represent novel diagnostic or prognostic markers, as well as therapeutic targets, for patients with UCC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18676751     DOI: 10.1158/1078-0432.CCR-08-0731

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  101 in total

1.  B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation.

Authors:  Hao Liu; Christina Tekle; Yih-Wen Chen; Alexandr Kristian; Yuhua Zhao; Ming Zhou; Zixing Liu; Yan Ding; Bin Wang; Gunhild Mari Mælandsmo; Jahn Marthin Nesland; Oystein Fodstad; Ming Tan
Journal:  Mol Cancer Ther       Date:  2011-04-25       Impact factor: 6.261

Review 2.  Immunotherapies for bladder cancer: a new hope.

Authors:  Farhad Fakhrejahani; Yusuke Tomita; Agnes Maj-Hes; Jane B Trepel; Maria De Santis; Andrea B Apolo
Journal:  Curr Opin Urol       Date:  2015-11       Impact factor: 2.309

Review 3.  Muscle-invasive urothelial bladder cancer: an update on systemic therapy.

Authors:  Hayley Knollman; J Luke Godwin; Rishi Jain; Yu-Ning Wong; Elizabeth R Plimack; Daniel M Geynisman
Journal:  Ther Adv Urol       Date:  2015-12

Review 4.  New Strategies in Bladder Cancer: A Second Coming for Immunotherapy.

Authors:  Ali Ghasemzadeh; Trinity J Bivalacqua; Noah M Hahn; Charles G Drake
Journal:  Clin Cancer Res       Date:  2015-12-18       Impact factor: 12.531

5.  B7-H3 Expression in Merkel Cell Carcinoma-Associated Endothelial Cells Correlates with Locally Aggressive Primary Tumor Features and Increased Vascular Density.

Authors:  Phyu P Aung; Edwin Roger Parra; Souptik Barua; Dawen Sui; Jing Ning; Barbara Mino; Debora Alejandra Ledesma; Jonathan L Curry; Priyadharsini Nagarajan; Carlos A Torres-Cabala; Eleni Efstathiou; Anh G Hoang; Michael K Wong; Jennifer A Wargo; Alexander J Lazar; Arvind Rao; Victor G Prieto; Ignacio Wistuba; Michael T Tetzlaff
Journal:  Clin Cancer Res       Date:  2019-02-26       Impact factor: 12.531

6.  Relationship between the expression of PD-1/PD-L1 and 18F-FDG uptake in bladder cancer.

Authors:  Ruohua Chen; Xiang Zhou; Jianjun Liu; Gang Huang
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-09       Impact factor: 9.236

7.  PDL1: The Illusion of an Ideal Biomarker.

Authors:  Andrea B Apolo
Journal:  Eur Urol Focus       Date:  2015-06-06

8.  High expression of B7-H3 and CD163 in cancer tissues indicates malignant clinicopathological status and poor prognosis of patients with urothelial cell carcinoma of the bladder.

Authors:  Zhili Xu; Ling Wang; Jianhua Tian; Hongwei Man; Pengfei Li; Baoen Shan
Journal:  Oncol Lett       Date:  2018-03-05       Impact factor: 2.967

9.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.

Authors:  Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer
Journal:  Lancet       Date:  2016-03-04       Impact factor: 79.321

Review 10.  The complex role of B7 molecules in tumor immunology.

Authors:  Barbara Seliger; Francesco M Marincola; Soldano Ferrone; Hinrich Abken
Journal:  Trends Mol Med       Date:  2008-11-03       Impact factor: 11.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.